| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley, Deborah Stocken, Stephen C Gough, Jeremy W Tomlinson, Rachel M Brown, Stefan G Hübscher, Philip N Newsom. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England). vol 387. issue 10019. 2016-03-07. PMID:26608256. |
glucagon-like peptide-1 (glp-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models of fatty liver disease. |
2016-03-07 |
2023-08-13 |
Not clear |
| Joseph P Tiano, Chandra R Tate, Bin S Yang, Richard DiMarchi, Franck Mauvais-Jarvi. Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis. Scientific reports. vol 5. 2016-03-04. PMID:25970118. |
in cultured human islets and in c57bl/6 mice, both aglp1 and aglp1-e2 enhanced glucose-stimulated insulin secretion (gsis) compared to vehicle and iglp1-e2 without superior efficacy of aglp1-e2 compared to glp-1 alone. |
2016-03-04 |
2023-08-13 |
mouse |
| Joseph P Tiano, Chandra R Tate, Bin S Yang, Richard DiMarchi, Franck Mauvais-Jarvi. Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis. Scientific reports. vol 5. 2016-03-04. PMID:25970118. |
however, combining glp-1 to estrogen delivers additional efficacy relative to glp-1 alone on insulin sensitivity and glucose homeostasis in non-diabetic mice. |
2016-03-04 |
2023-08-13 |
mouse |
| Sheila A Doggrel. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes? Reviews on recent clinical trials. vol 10. issue 1. 2016-03-03. PMID:25881636. |
the revelation that insulin secretion is under the control of a gut hormone, glucagon-like peptide 1 (glp-1), led to a new paradigm in the management of type 2 diabetes. |
2016-03-03 |
2023-08-13 |
human |
| John P Vu, Deepinder Goyal, Leon Luong, Suwan Oh, Ravneet Sandhu, Joshua Norris, William Parsons, Joseph R Pisegna, Patrizia M German. PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin. American journal of physiology. Gastrointestinal and liver physiology. vol 309. issue 10. 2016-02-25. PMID:26336928. |
active ghrelin, glucagon-like peptide-1 (glp-1), leptin, peptide yy, pancreatic polypeptide, and insulin were measured following pacap1-38 administration in fasted wt mice. |
2016-02-25 |
2023-08-13 |
mouse |
| John P Vu, Deepinder Goyal, Leon Luong, Suwan Oh, Ravneet Sandhu, Joshua Norris, William Parsons, Joseph R Pisegna, Patrizia M German. PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin. American journal of physiology. Gastrointestinal and liver physiology. vol 309. issue 10. 2016-02-25. PMID:26336928. |
in pac1-/- mice, fasting levels of active ghrelin, glp-1, insulin, and leptin and postprandial levels of active ghrelin and insulin were significantly altered compared with levels in wt mice. |
2016-02-25 |
2023-08-13 |
mouse |
| Fei Wang, Stephanie M Yoder, Qing Yang, Alison B Kohan, Tammy L Kindel, Jacob Wang, Patrick Ts. Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight. American journal of physiology. Gastrointestinal and liver physiology. vol 309. issue 10. 2016-02-25. PMID:26336929. |
the incretin hormones, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), enhance postprandial insulin secretion, promote adipogenesis, and regulate gastrointestinal motility and food intake. |
2016-02-25 |
2023-08-13 |
rat |
| Maharshi Bhaswant, Hemant Poudyal, Lindsay Brow. Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. The Journal of nutritional biochemistry. vol 26. issue 6. 2016-02-24. PMID:25841249. |
the complex actions of epa include increased g-protein-receptor-mediated release of glucagon-like peptide 1 (glp-1) from enteroendocrine l-cells in the intestine, up-regulation of the apelin pathway and down-regulation of other control pathways to promote insulin secretion by the pancreatic β-cells, together with suppression of inflammatory responses to adipokines, inhibition of peroxisome proliferator-activated receptor α actions and prevention of decreased insulin-like growth factor-1 secretion to improve peripheral insulin responses. |
2016-02-24 |
2023-08-13 |
Not clear |
| Maharshi Bhaswant, Hemant Poudyal, Lindsay Brow. Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. The Journal of nutritional biochemistry. vol 26. issue 6. 2016-02-24. PMID:25841249. |
modifying both glp-1 release and the actions of adipokines by n-3 pufas could lead to additive improvements in both insulin secretion and sensitivity. |
2016-02-24 |
2023-08-13 |
Not clear |
| Martin Heni, Stephanie Kullmann, Baptist Gallwitz, Hans-Ulrich Häring, Hubert Preissl, Andreas Fritsch. Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans. Molecular metabolism. vol 4. issue 12. 2016-02-24. PMID:26909313. |
dissociation of glp-1 and insulin association with food processing in the brain: glp-1 sensitivity despite insulin resistance in obese humans. |
2016-02-24 |
2023-08-13 |
Not clear |
| Charles F Shaefer, Pamela Kushner, Richard Aguila. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate medicine. vol 127. issue 8. 2016-02-18. PMID:26371721. |
these agents work by activating glp-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release-responses that are both glucose-dependent-with a consequent low risk for hypoglycemia. |
2016-02-18 |
2023-08-13 |
Not clear |
| Jaime A Davidso. Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy. Postgraduate medicine. vol 127. issue 8. 2016-02-18. PMID:26428031. |
glucagon-like peptide-1 receptor agonists (glp-1 ras) mimic the action of the endogenous gastrointestinal hormone glp-1 to activate the insulin response in pancreatic beta cells in a glucose-dependent manner. |
2016-02-18 |
2023-08-13 |
Not clear |
| Rune Ehrenreich Kuhre, Nicolai Jacob Wewer Albrechtsen, Bolette Hartmann, Carolyn F Deacon, Jens Juul Hols. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of diabetes and its complications. vol 29. issue 3. 2016-02-16. PMID:25623632. |
the two incretin hormones, glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic peptide (gip), are secreted from the gastrointestinal tract in response to meals and contribute to the regulation of glucose homeostasis by increasing insulin secretion. |
2016-02-16 |
2023-08-13 |
Not clear |
| Jeffrey L Probstfield, Irl Hirsch, Kevin O'Brien, Barry Davis, Richard Bergenstal, Connie Kingry, Dori Khakpour, Sarah Pressel, Kelley R Branch, Matthew Riddl. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. Diabetes care. vol 38. issue 8. 2016-02-16. PMID:26068865. |
design of flat-sugar: randomized trial of prandial insulin versus prandial glp-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. |
2016-02-16 |
2023-08-13 |
Not clear |
| Hina Y Bhutta, Neetu Rajpal, Wendy White, Johannes M Freudenberg, Yaping Liu, James Way, Deepak Rajpal, David C Cooper, Andrew Young, Ali Tavakkoli, Lihong Che. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PloS one. vol 10. issue 3. 2016-02-09. PMID:25798945. |
to investigate the effect of rygb on ba physiology and its relationship with glucose homeostasis, we undertook rygb and sham surgery in zucker diabetic fatty (zdf) and normoglycemic sprague dawley (sd) rats and measured plasma and fecal ba levels, as well as plasma glucose, insulin, glucagon like peptide 1 (glp-1) and peptide yy (pyy), 2 days before and 3, 7, 14 and 28 days after surgery. |
2016-02-09 |
2023-08-13 |
rat |
| Hina Y Bhutta, Neetu Rajpal, Wendy White, Johannes M Freudenberg, Yaping Liu, James Way, Deepak Rajpal, David C Cooper, Andrew Young, Ali Tavakkoli, Lihong Che. Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PloS one. vol 10. issue 3. 2016-02-09. PMID:25798945. |
rygb decreased body weight and increased plasma glp-1 in both sd and zdf rats while decreasing plasma insulin and glucose in zdf rats starting from the first week. |
2016-02-09 |
2023-08-13 |
rat |
| Dan Ziegler, Alexander Strom, Klaus Strassburger, Bettina Nowotny, Lejla Zahiragic, Peter J Nowotny, Maren Carstensen-Kirberg, Christian Herder, Julia Szendroedi, Michael Rode. Differential Patterns and Determinants of Cardiac Autonomic Nerve Dysfunction during Endotoxemia and Oral Fat Load in Humans. PloS one. vol 10. issue 4. 2016-02-09. PMID:25893426. |
in conclusion, suppression of vagal tone and sympathetic predominance during endotoxemia are linked to anti-inflammatory processes and lipid oxidation but not to insulin resistance, while weaker hrv changes in relation to the glp-1 response are noted during oral fat load. |
2016-02-09 |
2023-08-13 |
human |
| Xiangchen Kong, Dan Yan, Xuerui Wu, Youfei Guan, Xiaosong M. Glucotoxicity inhibits cAMP-protein kinase A-potentiated glucose-stimulated insulin secretion in pancreatic β-cells. Journal of diabetes. vol 7. issue 3. 2016-02-08. PMID:24981285. |
we reported recently that glp-1 potentiates glucose-stimulated insulin secretion (gsis) mainly via activation of the camp-protein kinase a (pka) signaling pathway in ins-1e cells under hyperglycemic conditions. |
2016-02-08 |
2023-08-13 |
Not clear |
| Jelena Kolic, Patrick E MacDonal. cAMP-independent effects of GLP-1 on β cells. The Journal of clinical investigation. vol 125. issue 12. 2016-02-05. PMID:26571393. |
the ability of glucose to stimulate insulin secretion from the pancreatic islets of langerhans is enhanced by the intestinal hormone glucagon-like peptide 1 (glp-1), which is secreted from the gut in response to nutrient ingestion. |
2016-02-05 |
2023-08-13 |
Not clear |
| Jelena Kolic, Patrick E MacDonal. cAMP-independent effects of GLP-1 on β cells. The Journal of clinical investigation. vol 125. issue 12. 2016-02-05. PMID:26571393. |
this action, called the incretin effect, accounts for as much as half of the postprandial insulin response and is exploited therapeutically for diabetes treatment through the use of incretin mimetic drugs and inhibitors of dipeptidyl peptidase 4, which degrades glp-1. |
2016-02-05 |
2023-08-13 |
Not clear |